Inverse correlation between serum PGE2 and T classification in head and neck cancer

Head and Neck

Volumn 29, Issue 3, 2007, Pages 244-248

  Hambek, Markus ^a   Baghi, Mehran ^a   Wagenblast, Jens ^a   Schmitt, Johannes ^a   Baumann, Helena ^a   Knecht, Rainald ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Early stage cancer; Head and neck cancer; PGE2; Serum analysis

Indexed keywords

PROSTAGLANDIN E2;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER STAGING; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; SERUM; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DINOPROSTONE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 33847421749     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20503     Document Type: Article

References (22)

1. Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-1628.
2. Ye F, Wu J, Dunn T, Yi J, Tong X, Zhang D. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett 2004;211:39-46.
3. Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther 2004;3:847-852.
4. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001;22:17-25.
5. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-714.
6. Kanda N, Watanabe S. Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid carcinoma A-431 cells. J Invest Dermatol 2002;119:174-181.
7. Papa F, Scacco S, Vergari R, et al. Expression and subcellular distribution of Bcl-2 and BAX proteins in serum-starved human keratinocytes and mouth carcinoma epidermoid cultures. Life Sci 2003;73:2865-2872.
8. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EPS. FEBS Lett 2002;518:154-158.
9. 2+ influx and cyclic GMP formation in mouse neuroblastoma X rat glioma hybrid NG108-15 cells in culture. J Neurochem 1988;50:1418-1424.
10. Wu YY, Lin MC. Induction of differentiation in v-Ha-ras-transformed MDCK cells by prostaglandin E2 and 8-bromo-cyclic AMP is associated with a decrease in steady-state level of inositol 1,4,5-trisphosphate. Mol Cell Biol 1990;10:57-67.
11. Sato T, Nakajima H, Fujio K, Mori Y. Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells. Prostaglandins 1997;53:355-369.
12. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. APC deficiency is associated with increased EGFR activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004;279:43261-43272.
13. Wang W, Andersson M, Lonnroth C, Svanberg E, Lundholm K. Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: a model with prostanoid-related cachexia. Int J Cancer 2005;115:582-590.
14. Maeda Y, Sasaki T, Mochizuki M, Koike M. Esophageal carcinoma with hypercalcemia that appeared to be caused by prostaglandin E2 produced by the tumor cells. Gan No Rinsho 1990;36:2445-2449.
15. Todo S, Imashuku S, Inoda H, et al. Hypercalcemia in a case of childhood acute lymphoblastic leukemia. Jpn J Clin Oncol 1987;17:357-362.
16. Takeuchi T, Takeuchi H, Hoshino R, Ohmi K. Rhabdo-myosarcoma-induced hypercalcemia in a nude mouse. Cancer 1982;50:94-96.
17. Smith KL, Tisdale MJ. Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 1993;68:314-318.
18. Starczewski M, Voigtmann R, Peskar BA, Peskar BM. Plasma levels of 15-keto-13,14-dihydro-prostaglandin E2 in patients with bronchogenic carcinoma. Prostaglandins Leukot Med 1984;13:249-258.
19. Malachi T, Chaimoff C, Feller N, Halbrecht I. Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J Cancer Res Clin Oncol 1981;102:71-79.
20. Sudbo J, Ristimaki A, Sondresen JE, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003;39:497-505.
21. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65:664-670.
22. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005;26:1393-1399.